Abstract | BACKGROUND: OBJECTIVE: Our purpose was to determine the efficacy of colchicine in the treatment of EBA. METHODS: Four patients with severe EBA refractory to conventional therapy were treated with colchicine 0.6 to 1.5 mg a day for up to 4 years. RESULTS: In all four patients the lessening of skin fragility and the decrease in spontaneous blister formation were dramatic; few side effects were noted. CONCLUSION:
Colchicine should be considered in the treatment of EBA.
|
Authors | B B Cunningham, T T Kirchmann, D Woodley |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 34
Issue 5 Pt 1
Pg. 781-4
(May 1996)
ISSN: 0190-9622 [Print] United States |
PMID | 8632074
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Dermatologic Agents
- Immunoglobulin G
- Colchicine
|
Topics |
- Adult
- Aged
- Colchicine
(administration & dosage, therapeutic use)
- Dermatologic Agents
(therapeutic use)
- Diagnosis, Differential
- Epidermis
(pathology)
- Epidermolysis Bullosa Acquisita
(drug therapy, pathology)
- Female
- Fluorescent Antibody Technique, Direct
- Follow-Up Studies
- Humans
- Immunoglobulin G
(analysis)
- Male
- Pemphigoid, Bullous
(pathology)
- Remission Induction
- Skin
(drug effects, pathology)
|